公司资料
Assertio 股价、新闻与催化剂
- 股票代码:
- ASRT
- 交易所:
- NASDAQ
- 行业:
- Biopharma
- 所在地:
- United States
股票表现
23.50 USD (+0.13%)
收盘价
最后更新: 2026年6月15日
152M USD
市值
股价为何变动
目前无法获取 ASRT 的收盘价变动背景。
公司概览
Specialty Pharmaceutical Company
Assertio Holdings commercializes differentiated prescription products, with its current strategy centered primarily on oncology supportive care. The company has assembled its portfolio through acquisitions and licensing transactions and operates commercial, market-access, trade, and distribution capabilities.
Rolvedon Oncology Franchise
Rolvedon, or eflapegrastim-xnst, is a long-acting granulocyte colony-stimulating factor used to reduce the incidence of infection manifested by febrile neutropenia in adults receiving myelosuppressive anticancer therapy. It is the company's lead product and is promoted to both hospital systems and community oncology practices.
Sympazan Neurology Product
Sympazan is an oral film formulation of clobazam used as adjunctive treatment for seizures associated with Lennox-Gastaut syndrome in patients aged two years and older. The film adheres to the tongue and can serve patients who have difficulty swallowing conventional tablets or liquids.
Hospital and Pain Products
The remaining marketed portfolio includes INDOCIN formulations, SPRIX ketorolac nasal spray, and CAMBIA diclofenac oral solution. These products address hospital, acute-pain, migraine, and inflammatory-care settings, although they are less central to the company's current oncology-focused strategy.
Acquisition-Led Commercial Model
Assertio seeks approved or late-stage products that can be supported through its existing infrastructure. Centralized commercialization and portfolio integration allow the company to manage products across multiple specialty channels without operating a broad internal research platform.
未来催化剂
近期新闻
新闻标题由机器翻译，详情为英文原文。
- 01
- 02
- 03
- 04
- 05
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。